Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2014, Article ID 269613, 6 pages
http://dx.doi.org/10.1155/2014/269613
Clinical Study

Alendronate as an Effective Treatment for Bone Loss and Vascular Calcification in Kidney Transplant Recipients

Division of Nephrology, Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama City, Wakayama 641-0012, Japan

Received 21 November 2013; Accepted 15 January 2014; Published 19 February 2014

Academic Editor: Bruce Kaplan

Copyright © 2014 Masanori Okamoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Kodras and M. Haas, “Effect of kidney transplantation on bone,” European Journal of Clinical Investigation, vol. 36, no. 2, pp. 63–75, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. R. Parker, A. J. Freemont, P. J. Blackwell, M. J. Grainge, and D. J. Hosking, “Cross-sectional analysis of renal transplantation osteoporosis,” Journal of Bone and Mineral Research, vol. 14, no. 11, pp. 1943–1951, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-P. Casez, K. Lippuner, F. F. Horber, A. Montandon, and P. Jaeger, “Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone,” Nephrology Dialysis Transplantation, vol. 17, no. 7, pp. 1318–1326, 2002. View at Google Scholar · View at Scopus
  4. E. Tutal, M. E. Uyar, T. Colak et al., “Low graft function and ongoing hyperparathyroidism are closely related to post-transplantation osteoporosis,” Transplantation Proceedings, vol. 45, pp. 1562–1566, 2013. View at Google Scholar
  5. K. Kalantar-Zadeh, M. Z. Molnar, C. P. Kovesdy et al., “Management of mineral and bone disorder after kidney transplantation,” Current Opinion in Nephrology and Hypertension, vol. 21, pp. 389–403, 2012. View at Google Scholar
  6. G. Coen, “Fracturing osteoporosis after kidney transplantation—what are the options?” Nephrology Dialysis Transplantation, vol. 11, no. 4, pp. 567–569, 1996. View at Google Scholar · View at Scopus
  7. A. V. Cayco, J. Wysolmerski, C. Simpson et al., “Posttransplant bone disease: evidence for a high bone resorption state,” Transplantation, vol. 70, no. 12, pp. 1722–1728, 2000. View at Google Scholar · View at Scopus
  8. C. Mitterbauer and R. Oberbauer, “Bone disease after kidney transplantation,” Transplant International, vol. 21, no. 7, pp. 615–624, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. P. van Staa, H. G. M. Leufkens, L. Abenhaim, B. Zhang, and C. Cooper, “Use of oral corticosteroids and risk of fractures,” Journal of Bone and Mineral Research, vol. 15, no. 6, pp. 993–1000, 2000. View at Google Scholar · View at Scopus
  10. A. Ugur, N. Guvener, I. Iklar, M. Turan, R. Erdal, and M. Haberal, “Osteoporosis after renal transplantation: single center experience,” Transplantation, vol. 71, no. 5, pp. 645–649, 2001. View at Google Scholar · View at Scopus
  11. R. Marcén, C. Caballero, J. Pascual et al., “Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study,” Transplantation, vol. 81, no. 6, pp. 826–831, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. U. A. Liberman, S. R. Weiss, J. Bröll et al., “Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group,” The New England Journal of Medicine, vol. 333, no. 22, pp. 1437–1443, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. J. D. Adachi, W. G. Bensen, J. Brown et al., “Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis,” The New England Journal of Medicine, vol. 337, no. 6, pp. 382–387, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. G. N. Farhat, J. A. Cauley, K. A. Matthews et al., “Volumetric BMD and vascular calcification in middle-aged women: the study of women's health across the nation,” Journal of Bone and Mineral Research, vol. 21, no. 12, pp. 1839–1846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. G. N. Farhat, E. S. Strotmeyer, A. B. Newman et al., “Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study,” Calcified Tissue International, vol. 79, no. 2, pp. 102–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Schulz, K. Arfai, X. Liu, J. Sayre, and V. Gilsanz, “Aortic calcification and the risk of osteoporosis and fractures,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4246–4253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. E. Hak, H. A. P. Pols, A. M. van Hemert, A. Hofman, and J. C. M. Witteman, “Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 8, pp. 1926–1931, 2000. View at Google Scholar · View at Scopus
  18. L. B. Tanko, C. Christiansen, D. A. Cox et al., “Relationship between osteoporosis and cardiovascular disease in postmenopausal women,” Journal of Bone and Mineral Research, vol. 20, pp. 1912–1920, 2005. View at Google Scholar
  19. W. S. Browner, D. G. Seeley, T. M. Vogt, and S. R. Cummings, “Non-trauma mortality in elderly women with low bone mineral density. Study of osteoporotic fractures research group,” The Lancet, vol. 338, no. 8763, pp. 355–358, 1991. View at Publisher · View at Google Scholar · View at Scopus
  20. G. M. London, C. Marty, S. J. Marchais, A. P. Guerin, F. Metivier, and M.-C. de Vernejoul, “Arterial calcifications and bone histomorphometry in end-stage renal disease,” Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1943–1951, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Braun, M. Oldendorf, W. Moshage, R. Heidler, E. Zeitler, and F. C. Luft, “Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients,” The American Journal of Kidney Diseases, vol. 27, no. 3, pp. 394–401, 1996. View at Google Scholar · View at Scopus
  22. S. M. Moe and N. X. Chen, “Vascular calcification in end stage renal disease,” Clinical Calcium, vol. 12, pp. 1417–1422, 2002. View at Google Scholar
  23. C. Marchal, E. Coche, E. Goffin et al., “Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients,” The American Journal of Kidney Diseases, vol. 59, no. 2, pp. 258–269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Lehmann, U. Ott, G. Stein, T. Steiner, and G. Wolf, “Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients,” Transplantation Proceedings, vol. 39, no. 10, pp. 3153–3158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Oschatz, T. Benesch, K. Kodras, U. Hoffmann, and M. Haas, “Changes of coronary calcification after kidney transplantation,” The American Journal of Kidney Diseases, vol. 48, no. 2, pp. 307–313, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. K. A. Lomashvili, M.-C. Monier-Faugere, X. Wang, H. H. Malluche, and W. C. O'Neill, “Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure,” Kidney International, vol. 75, no. 6, pp. 617–625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Nitta, T. Akiba, K. Suzuki et al., “Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis,” The American Journal of Kidney Diseases, vol. 44, no. 4, pp. 680–688, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Ariyoshi, K. Eishi, I. Sakamoto, S. Matsukuma, and T. Odate, “Effect of etidronic acid on arterial calcification in dialysis patients,” Clinical Drug Investigation, vol. 26, no. 4, pp. 215–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Mainra and G. Elder, “Review article: managing bone complications after kidney transplantation,” Nephrology, vol. 14, no. 4, pp. 437–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. L. I. Plotkin, R. S. Weinstein, A. M. Parfitt, P. K. Roberson, S. C. Manolagas, and T. Bellido, “Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin,” Journal of Clinical Investigation, vol. 104, no. 10, pp. 1363–1374, 1999. View at Google Scholar · View at Scopus
  31. W. Grotz, C. Nagel, D. Poeschel et al., “Effect of ibandronate on bone loss and renal function after kidney transplantation,” Journal of the American Society of Nephrology, vol. 12, no. 7, pp. 1530–1537, 2001. View at Google Scholar · View at Scopus
  32. M. Coco, D. Glicklich, M. C. Faugere et al., “Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate,” Journal of the American Society of Nephrology, vol. 14, no. 10, pp. 2669–2676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. J. R. Jeffery, W. D. Leslie, M. E. Karpinski, P. W. Nickerson, and D. N. Rush, “Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate,” Transplantation, vol. 76, no. 10, pp. 1498–1502, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. A. E. El-Agroudy, A. A. El-Husseini, M. El-Sayed, T. Mohsen, and M. A. Ghoneim, “A prospective randomized study for prevention of postrenal transplantation bone loss,” Kidney International, vol. 67, no. 5, pp. 2039–2045, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Haas, Z. Leko-Mohr, P. Roschger et al., “Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation,” Kidney International, vol. 63, no. 3, pp. 1130–1136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. J. V. Torregrosa, D. Fuster, S. Pedroso et al., “Weekly risedronate in kidney transplant patients with osteopenia,” Transplant International, vol. 20, no. 8, pp. 708–711, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Abediazar and M. R. Nakhjavani, “Effect of alendronate on early bone loss of renal transplant recipients,” Transplantation Proceedings, vol. 43, no. 2, pp. 565–567, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S. L.-S. Fan, M. K. Almond, E. Ball, K. Evans, and J. Cunningham, “Pamidronate therapy as prevention of bone loss following renal transplantation,” Kidney International, vol. 57, no. 2, pp. 684–690, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Cunningham, “Bisphosphonates in the renal patient,” Nephrology Dialysis Transplantation, vol. 22, no. 6, pp. 1505–1507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. R. N. Foley, P. S. Parfrey, and M. J. Sarnak, “Clinical epidemiology of cardiovascular disease in chronic renal disease,” The American Journal of Kidney Diseases, vol. 32, no. 5, supplement 3, pp. S112–S119, 1998. View at Google Scholar · View at Scopus
  41. B. L. Kasiske, “Cardiovascular disease after renal transplantation,” Seminars in Nephrology, vol. 20, no. 2, pp. 176–187, 2000. View at Google Scholar · View at Scopus
  42. N. D. Toussaint, G. J. Elder, and P. G. Kerr, “Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 1, pp. 221–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. H. A. Fleisch, R. G. Russell, S. Bisaz, R. C. Mühlbauer, and D. A. Williams, “The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo,” European Journal of Clinical Investigation, vol. 1, no. 1, pp. 12–18, 1970. View at Google Scholar · View at Scopus
  44. R. G. Russell, R. Smith, M. C. Bishop, and D. A. Price, “Treatment of myositis ossificans progressiva with a diphosphonate,” The Lancet, vol. 1, no. 7740, pp. 10–11, 1972. View at Google Scholar · View at Scopus
  45. E. Saito, H. Wachi, F. Sato, H. Sugitani, and Y. Seyama, “Treatment with vitamin K(2) combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells,” Journal of Atherosclerosis and Thrombosis, vol. 14, no. 6, pp. 317–324, 2007. View at Google Scholar · View at Scopus
  46. P. A. Price, A. M. Roublick, and M. K. Williamson, “Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate,” Kidney International, vol. 70, no. 9, pp. 1577–1583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. K. Tamura, Y. Suzuki, M. Matsushita et al., “Prevention of aortic calcification by etidronate in the renal failure rat model,” European Journal of Pharmacology, vol. 558, no. 1–3, pp. 159–166, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Persy, M. de Broe, and M. Ketteler, “Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels?” Kidney International, vol. 70, no. 9, pp. 1537–1538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Zhou, X. Fang, H. Xin et al., “Effect of alendronate on the Notch 1-RBP-Jk signaling pathway in the osteogenic differentiation and mineralization of vascular smooth muscle cells,” Molecular Medicine Reports, vol. 8, pp. 89–94, 2013. View at Google Scholar
  50. P. Jia, Y. Li, J. Wang, F. Zhang, K. Liu, and Z. Wang, “The effect of alendronate on the expression of osteopontin and osteoprotegerin in calcified aortic tissue of the rat,” European Journal of Pharmacology, vol. 682, no. 1–3, pp. 126–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Hashiba, S. Aizawa, K. Tamura, T. Shigematsu, and H. Kogo, “Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients,” Therapeutic Apheresis and Dialysis, vol. 8, no. 3, pp. 241–247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. S. M. Ott, “Long-term safety of bisphosphonates,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1897–1899, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Elmariah, J. A. C. Delaney, K. D. O’Brien et al., “Bisphosphonate use and prevalence of valvular and vascular calcification in women: MESA (The Multi-Ethnic Study of Atherosclerosis),” Journal of the American College of Cardiology, vol. 56, no. 21, pp. 1752–1759, 2010. View at Publisher · View at Google Scholar · View at Scopus